` NKGN (NKGen Biotech Inc) vs S&P 500 Comparison - Alpha Spread

N
NKGN
vs
S&P 500

Over the past 12 months, NKGN has underperformed S&P 500, delivering a return of -92% compared to the S&P 500's +14% growth.

Stocks Performance
NKGN vs S&P 500

Loading
NKGN
S&P 500
Add Stock
www.alphaspread.com
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Performance Gap
NKGN vs S&P 500

Loading
NKGN
S&P 500
Difference
www.alphaspread.com

Performance By Year
NKGN vs S&P 500

Loading
NKGN
S&P 500
Add Stock
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Competitors Performance
NKGen Biotech Inc vs Peers

S&P 500
NKGN
539112
SLB
RDDT
BKR
Add Stock
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

NKGen Biotech Inc
Glance View

Market Cap
6.2m USD
Industry
N/A

NKGen Biotech Inc is a US-based company operating in industry. The company is headquartered in Santa Ana, California. The company went IPO on 2021-05-21. NKGen Biotech, Inc. is a clinical-stage biotechnology company. The firm is focused on the development and commercialization of autologous, allogeneic, and CAR-NK natural killer cell therapies to treat neurodegenerative and oncological diseases utilizing its (SuperNK) SNK (super-activated) platform. SNK involves the infusion of one’s own activated NK cells into the body to improve immune system function, eliminate diseased or abnormal cells and prevent recurrence. SNK uses pure NK cells harvested from the patient’s blood, activated and infused back into the patient’s body. SNK has a therapeutic potential within the areas of cancer, autoimmune and neurodegenerative diseases. Autologous NK cell immunotherapy is a treatment that provides immune enhancement using pure NK cells harvested from a patient’s body. The company is also focused on conducting clinical trials with its super-activated NK cell therapy in patients with neurodegenerative disease (SNK01) and cancer (SNK02).

NKGN Intrinsic Value
Not Available
N
Back to Top